Innoviva, Inc.
NASDAQ: INVA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pavel Raifeld
- Employees
- 127
- Headquarters
- Burlingame, United States
- IPO year
- 2004
- Market cap
- $1.7B
- Website
- https://www.inva.com
Loading INVA…
Loading profile data…Frequently asked questions about INVA
What does Innoviva, Inc. (INVA) do?
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled c...
Where does INVA trade?
Innoviva, Inc. (INVA) trades on the NASDAQ Global Select.
What sector is INVA in?
Innoviva, Inc. (INVA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Innoviva, Inc.?
Pavel Raifeld is the chief executive officer of Innoviva, Inc. (INVA).
Where is Innoviva, Inc. headquartered?
Innoviva, Inc. is headquartered in United States.
Does INVA pay a dividend?
Innoviva, Inc. (INVA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INVA go public?
Innoviva, Inc. (INVA) completed its initial public offering in 2004.